https://mindmedicinelaw.com/briefing/esketamine-biomarker-study-in-trd-metabolic-burden-insights-20260907-39755The Psychedelic Journalen2026-09-07T22:05:09.140210+00:00Esketamine Biomarker Study in TRD: Metabolic Burden Insightsesketamine, treatment-resistant depression, metabolic burden, biomarkers, clinical trials, patient stratification, adverse effects, personalized medicine, psychedelic therapyhttps://mindmedicinelaw.com/briefing/metabolomic-insights-from-iv-ketamine-in-trd-bio-k-nndc-us-multicenter-trial-20260906-39757The Psychedelic Journalen2026-09-07T22:04:44.546063+00:00Metabolomic Insights from IV Ketamine in TRD: Bio-K/NNDC US Multicenter Trialketamine, treatment-resistant depression, metabolomics, biomarkers, clinical trials, mechanism of action, psychiatry, biocrates mxp q500, gaba, madrshttps://mindmedicinelaw.com/briefing/metabolomic-insights-from-bio-k-nndc-iv-ketamine-trial-in-trd-20260906-39756The Psychedelic Journalen2026-09-07T22:04:30.236039+00:00Metabolomic Insights from Bio-K/NNDC IV Ketamine Trial in TRDketamine, treatment-resistant depression, metabolomics, biomarkers, clinical trials, psychiatric research, mitochondrial function, GABA, FDA regulation, precision psychiatryhttps://mindmedicinelaw.com/briefing/psilocybin-as-anxiolytic-mechanisms-evidence-and-regulatory-outlook-20260905-39746The Psychedelic Journalen2026-09-07T22:05:20.716818+00:00Psilocybin as Anxiolytic: Mechanisms, Evidence, and Regulatory Outlookpsilocybin, anxiolytic, mechanism of action, clinical trials, regulatory outlook, serotonin 2A receptor, neuroplasticity, policy implications, safety risks, psychedelic therapyhttps://mindmedicinelaw.com/briefing/phase-2-satoprodil-trials-in-mdd-no-benefit-over-placebo-20260905-39760The Psychedelic Journalen2026-09-07T22:04:59.332558+00:00Phase 2 Satoprodil Trials in MDD: No Benefit Over Placebosatoprodil, nmda receptor, glun2b modulator, major depressive disorder, phase 2 clinical trial, glutamatergic hypothesis, antidepressant development, placebo response, psychedelic-adjacent compoundshttps://mindmedicinelaw.com/briefing/tech-leaders-investments-reshape-u-s-psychedelics-market-trajectory-20260905-39505The Psychedelic Journalen2026-09-06T22:04:33.634395+00:00Tech Leaders’ Investments Reshape U.S. Psychedelics Market Trajectorypsychedelics, elon musk, tech investment, mainstreaming, clinical trials, fda, digital health, regulatory policy, public health, access modelshttps://mindmedicinelaw.com/briefing/stakeholder-attitudes-toward-psychedelic-therapy-in-ireland-2026-survey-insights-20260904-39388The Psychedelic Journalen2026-09-06T22:04:56.416302+00:00Stakeholder Attitudes Toward Psychedelic Therapy in Ireland: 2026 Survey Insightspsychedelic-assisted therapy, ireland, stakeholder survey, policy barriers, clinical trials, regulatory reform, public health, mental health innovation, training and infrastructure, risk perceptionhttps://mindmedicinelaw.com/briefing/synapto-nuclear-signaling-in-als-implications-for-neuroplasticity-research-20260904-39431The Psychedelic Journalen2026-09-06T22:04:44.854025+00:00Synapto-Nuclear Signaling in ALS: Implications for Neuroplasticity Researchsynapto-nuclear signaling, als, motoneuron vulnerability, cAMP/PKA signaling, neuroplasticity, pharmacological intervention, creb phosphorylation, psychedelics, neurodegenerative disease, preclinical researchhttps://mindmedicinelaw.com/briefing/eeg-study-reveals-psilocybin-s-distinct-acute-and-sub-acute-effects-in-healthy-a-20260904-39389The Psychedelic Journalen2026-09-06T22:04:21.534761+00:00EEG Study Reveals Psilocybin's Distinct Acute and Sub-Acute Effects in Healthy Adultspsilocybin, eeg biomarkers, sub-acute effects, clinical trial design, personalized medicine, neurophysiology, psychedelic therapy, afterglow, signal diversity, delta theta powerhttps://mindmedicinelaw.com/briefing/new-zealand-authorizes-mdma-prescription-for-severe-ptsd-20260904-39343The Psychedelic Journalen2026-09-06T15:04:00.071217+00:00New Zealand Authorizes MDMA Prescription for Severe PTSDmdma prescription, new zealand policy, psychedelic regulation, ptsd treatment, psychiatrist guidelines, real-world evidence, clinical adoption, regulatory precedent, adverse event reportinghttps://mindmedicinelaw.com/briefing/emergency-department-drug-detection-study-guides-harm-reduction-policy-20260903-39735The Psychedelic Journalen2026-09-07T22:05:31.270911+00:00Emergency Department Drug Detection Study Guides Harm Reduction Policyemergency department, drug detection, novel psychoactive substances, early warning system, harm reduction, public health surveillance, forensic toxicology, MDMA, methamphetamine, clinical protocolshttps://mindmedicinelaw.com/briefing/ketamine-dose-dependent-effects-implications-for-ambulatory-anesthesia-policy-20260903-39312The Psychedelic Journalen2026-09-06T15:04:14.472835+00:00Ketamine Dose-Dependent Effects: Implications for Ambulatory Anesthesia Policyketamine anesthesia, dose-dependent effects, respiratory depression, cortical function, ambulatory anesthesia, clinical safety, regulatory policy, psychiatric off-label use, monitoring protocolshttps://mindmedicinelaw.com/briefing/nac-proteomic-signatures-and-antidepressant-response-insights-from-rat-models-20260901-39730The Psychedelic Journalen2026-09-07T22:05:42.414330+00:00NAc Proteomic Signatures and Antidepressant Response: Insights from Rat Modelsnucleus accumbens, proteomics, stress vulnerability, antidepressant response, rat models, precision psychiatry, treatment-resistant depression, biomarkers, psychedelic researchhttps://mindmedicinelaw.com/briefing/hormonal-modulation-of-psilocybin-response-implications-for-female-patients-20260831-39739The Psychedelic Journalen2026-09-07T22:04:17.415020+00:00Hormonal Modulation of Psilocybin Response: Implications for Female Patientspsilocybin, female hormones, clinical trial design, PMDD, postpartum risk, personalized medicine, menopause, psychedelic safety, hormonal trackinghttps://mindmedicinelaw.com/briefing/s-ketamine-in-adolescent-psychosis-clinical-and-policy-implications-20260825-39503The Psychedelic Journalen2026-09-06T22:05:13.887220+00:00S-Ketamine in Adolescent Psychosis: Clinical and Policy Implicationss-ketamine, adolescent psychosis, suicidal ideation, treatment-resistant depression, case report, clinical trials, off-label use, policy implications, pediatric psychiatry